Explore Our Resource Library

Although most cancer drugs modulate the activities of cellular pathways by changing post-translational modifications (PTMs), surprisingly little is known regarding the extent and the time- and dose-response characteristics of drug-regulated PTMs. Here, we introduce a proteomic assay termed decryptM that quantifies drug-PTM modulation for thousands of PTMs in cells to shed light on target engagement and drug mechanism of action (MoA). Examples range from detecting DNA damage by chemotherapeutics, to identifying drug-specific PTM signatures of kinase inhibitors, to demonstrating that rituximab...

Several inhibitors of androgen receptor (AR) function are approved for prostate cancer treatment, and their impact on...

DNA-binding proteins are promising therapeutic targets but are notoriously difficult to drug. Here, we evaluate a...

Novel treatment options for metastatic colorectal cancer (CRC) are urgently needed to improve patient outcome. Here, we...

Mass Spectrometry-Based Analysis of Proteome-Wide Protein Stability We have used a mass spectrometry-based proteomic...

Glioblastoma is the most prevalent and aggressive brain cancer. With a median overall survival of ~15–20 months under...

Background & aims: Antibiotic (ABx) therapy is associated with increased risk for Crohn's disease but underlying...

Genome‐, transcriptome‐ and proteome‐wide measurements provide insights into how biological systems are regulated....